Skip to content

Study · Observational study · 2018

1 result

BIOCHEMICAL RESPONSES IN SYMPTOMATIC AND ASYMPTOMATIC PATIENTS WITH NEUROENDOCRINE TUMORS: POOLED ANALYSIS OF 2 PHASE 3 TRIALS.

Mirakhur B, Pavel ME, Pommier RF, Fisher GA, Phan AT, Massien C, Liyanage N, Lowenthal SP, Vinik AI

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists7 Aug 2018Cited by 5 (Europe PMC)

PMID30084687 (opens in a new tab)DOI10.4158/ep-2018-0296 (opens in a new tab)PepBankPUB-30084687
Source linkPubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanObservational studyEfficacy outcome

    In ELECT patients receiving lanreotide, biochemical response (≥50% decrease from baseline) was linked to greater carcinoid symptom control.

    In plain wordsAmong lanreotide recipients, biochemical response was linked to greater symptom control.

    Peptide
    Lanreotide
    Outcome
    IncreaseSymptom control by biochemical response
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    120 mg monthly · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    In ELECT, patients with CS who received lanreotide and experienced a biochemical response (≥50% decrease from baseline) achieved greater symptom control.
    1 context sentence
    Summary · context
    Patients were treated with subcutaneous lanreotide depot 120 mg monthly.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.